- Conditions
- Snakebite, Envenoming, Snake
- Interventions
- Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
- Drug
- Lead sponsor
- Ophirex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 802
matching trials from the live ClinicalTrials.gov search.
- Conditions
- End Stage Renal Disease, Chronic Kidney Diseases
- Interventions
- Berinert, Placebo
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
- Interventions
- Sodium Acetate, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Mapatumumab, Placebo, Sorafenib
- Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Mycophenolate mofeteil (MMF), Daclizumab (DZB), Placebo control for Mycophenolate mofeteil (MMF), Placebo control for Daclizumab (DZB)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 7 more
- Conditions
- Uterine Atony, Uterine Atony With Hemorrhage, Postpartum Hemorrhage, Cesarean Section Complications
- Interventions
- Calcium chloride, Saline placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Pacifica, California
- Conditions
- Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
- Interventions
- Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
- Procedure · Drug · Combination Product
- Lead sponsor
- Gary Van Guilder
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Gunnison, Colorado
- Conditions
- Social Anxiety Disorder
- Interventions
- Ketamine, Saline
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Hypotension, Blood Pressure
- Interventions
- Dopamine, Hydrocortisone, Infusion Placebo, Syringe Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 24 Hours
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
- Conditions
- Pneumonia
- Interventions
- TP-271
- Drug
- Lead sponsor
- Tetraphase Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Obesity
- Interventions
- Angiotensin-(1-7), Saline
- Drug
- Lead sponsor
- Amy Arnold
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Parkinson's Disease, Essential Tremor, Dystonia
- Interventions
- Dexmedetomidine Hydrochloride Infusion, Normal Saline
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hyperglycemia, Hypoglycemia
- Interventions
- GLP 1, normal saline solution placebo
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
- Interventions
- REGENECYTE, Placebo
- Biological
- Lead sponsor
- StemCyte, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Miami Lakes, Florida
- Conditions
- Atrial Fibrillation
- Interventions
- (R)-propafenone, (S)-Propafenone, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Rett Syndrome
- Interventions
- Intravenous infusion
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 5 Years to 25 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Critical Limb Ischemia
- Interventions
- RJX, Placebo
- Drug
- Lead sponsor
- Reven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Acute Ischemic Stroke
- Interventions
- Redasemtide, Placebo
- Biological · Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more
- Conditions
- PD Effects of GS-0976 (NDI-010976) on Fractional DNL
- Interventions
- GS-0976, Placebo, 1-13C acetate, Fructose solution
- Drug · Other
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Healthy
- Interventions
- Exendin-9,39, Saline
- Biological · Other
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy Volunteers
- Interventions
- TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cognitive Dysfunction
- Interventions
- N-acetylcysteine and ketamine, placebo and ketamine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
- Interventions
- AOC 1020, Placebo
- Drug
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more